Economic Burden of Patients with Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli

References

• Uslan DZ, Crane SJ, Steckelberg JM, et al. Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota. Arch Intern Med. 2007;167:834–839. doi:10.1001/archinte.167.8.83417452548
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-β-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother. 2005;49:2137.15855548
   PubMed Web of Science ®Google Scholar
• Meyer E, Ziegler R, Mattner F, Schwab F, Gastmeier P, Martin M. Increase of patients co-colonised or co-infected with methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium or extended-spectrum β-lactamase-producing Enterobacteriaceae. Infection. 2011;39(6):501–506. doi:10.1007/s15010-011-0154-021710119
   PubMed Web of Science ®Google Scholar
• Gajdács M, Ábrók M, Lázár A, Burián K. Comparative epidemiology and resistance trends of common urinary pathogens in a Tertiary-Care Hospital: a 10-year Surveillance Study. Medicina. 2019;55:356.
   Web of Science ®Google Scholar
• Gajdács M, Ábrók M, Lázár A, Burián K. Revival of older antibiotics for the therapy of urinary tract infections: old, but gold Part 1: antimicrobial susceptibility of extended-spectrum β-lactamase-producing and AmpC β-lactamase-producing: Escherichia coli: isolates. Rev Med Microbiol. 2020.
   Web of Science ®Google Scholar
• Zhang J, Zheng B, Zhao L, et al. Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in Escherichia coli isolated from patients with community-onset infections in Chinese county hospitals. BMC Infect Dis. 2014;14(1):659. doi:10.1186/s12879-014-0659-025466590
   PubMed Web of Science ®Google Scholar
• Sun Q, Tärnberg M, Zhao L, et al. Varying high levels of faecal carriage of extended-spectrum beta-lactamase producing Enterobacteriaceae in rural villages in Shandong, China: implications for global health. PLoS One. 2014;9:e113121. doi:10.1371/journal.pone.011312125405340
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhou Y, Guo S, Chang W. High prevalence and risk factors of fecal carriage of CTX-M type extended-spectrum beta-lactamase-producing Enterobacteriaceae from healthy rural residents of Taian, China. Front Microbiol. 2015;6:239.25870591
   PubMed Web of Science ®Google Scholar
• Zhong Y-M, Liu W-E, Liang X-H, Li Y-M, Jian Z-J, Hawkey PM. Emergence and spread of O16-ST131 and O25b-ST131 clones among faecal CTX-M-producing Escherichia coli in healthy individuals in Hunan Province, China. J Antimicrob Chemother. 2015;70(8):2223–2227. doi:10.1093/jac/dkv11425957581
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Spanu T, Di Bidino R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-β-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54(10):4085–4091. doi:10.1128/AAC.00143-1020660675
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and Economic Impact of bacteremia with extended- spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50:1257.16569837
   PubMed Web of Science ®Google Scholar
• Xiao T, Wu Z, Shi Q, et al. A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections. J Glob Antimicrob Resist. 2019;17:147–156.30634054
   PubMed Web of Science ®Google Scholar
• Stewardson A, Fankhauser C, Augelis GD, et al. Burden of bloodstream infection caused by extended-spectrum β-lactamase–producing enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a Nationwide Predictive Model. Infect Control Hosp Epidemiol. 2013;34(2):133–143. doi:10.1086/66908623295559
   PubMed Web of Science ®Google Scholar
• Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015;3:e712–e723.26475018
   PubMed Web of Science ®Google Scholar
• WHO methods and data sources for global burden of disease estimates 2000–2016. Available from: http://www.who.int/gho/mortality_burden_disease/en/index.html. Accessed 924, 2020.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 26th informational supplement. M100-S26; 2016; Wayne, Pennsylvania: Clinical and Laboratory Standards Institute.
   Google Scholar
• Gajdács M, Urbán E. Resistance Trends and Epidemiology of Citrobacter-Enterobacter-Serratia in Urinary Tract Infections of Inpatients and Outpatients (RECESUTI): a 10-year survey. Medicina. 2019;55:285.
   Web of Science ®Google Scholar
• Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–829.3928249
   PubMed Web of Science ®Google Scholar
• Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251. doi:10.1016/0895-4356(94)90129-57722560
   PubMed Web of Science ®Google Scholar
• Hill PC, Birch M, Chambers S, et al. Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality. Intern Med J. 2001;31(2):97–103. doi:10.1111/j.1444-0903.2001.00029.x11480485
   PubMed Web of Science ®Google Scholar
• China’s Gross Domestic Product (GDP). Available from: http://data.stats.gov.cn/search.htm?s=GDP.
   Google Scholar
• Barnum H. Evaluating healthy days of life gained from health projects. Soc Sci Med. 1987;24(10):833–841. doi:10.1016/0277-9536(87)90184-53112960
   PubMed Web of Science ®Google Scholar
• Murray CJL, Lopez AD. Global Health Statistics: A Com-Pendium of Incidence, Prevalence and Mortality Estimates Forover 200 Conditions. Cambridge, MA: Harvard University Press; 1996a.
   Google Scholar
• Murray CJL, Lopez AD, eds. The Global Burden of Disease: Acomprehensive Assessment of Mortality and Disability from Dis-Eases, Injuries, and Risk Factors in 1990 and Projected to 2020. TheGlobal Burden of Disease and Injury Series. Vol. 1 Boston, MA: Harvard University Press, for Harvard School of PublicHealth on behalf of the World Health Organisation and TheWorld Bank; 1996b.
   Google Scholar
• Murray CJ, Salomon JA, Mathers C. A critical examination of summary measures of population health. Bull World Health Organ. 2000;78:981–994.10994282
   PubMed Web of Science ®Google Scholar
• Disease, G. B. D., Injury, Incidence, and Prevalence, Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602.27733282
   PubMed Web of Science ®Google Scholar
• WHO methods and data sources for global burden of disease estimates 2000–2015. Available from: http://www.who.int/healthinfo/global_burden_disease/GlobalDALYmethods_2000_2015.pdf?ua=1. Accessed 924, 2020.
   Google Scholar
• Rottier WC, Ammerlaan HSM, Bonten MJM. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67:1311–1320.22396430
   PubMed Web of Science ®Google Scholar
• Zhen X, Lundborg CS, Sun X, Hu X, Dong H. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review. Antimicrob Resist Infect Control. 2019;8:137.31417673
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(12):2793–2803. doi:10.1093/jac/dks30122915465
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54:167–174.22057701
   PubMed Web of Science ®Google Scholar
• Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010;70:313–333. doi:10.2165/11533040-000000000-0000020166768
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect. 2008;14:180–183. doi:10.1111/j.1469-0691.2007.01884.x18005358
   PubMed Web of Science ®Google Scholar
• Bilavsky E, Temkin E, Lerman Y, et al. Risk factors for colonization with extended-spectrum beta-lactamase-producing enterobacteriaceae on admission to rehabilitation centres. Clin Microbiol Infect. 2014;20(11):O804–10. doi:10.1111/1469-0691.1263324674024
   PubMed Web of Science ®Google Scholar
• Wu UI, Yang CS, Chen WC, Chen YC, Chang SC. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. J Microbiol Immunol Infect. 2010;43:310–316. doi:10.1016/S1684-1182(10)60048-520688291
   PubMedGoogle Scholar
• Gudiol C, Calatayud L, Garcia-Vidal C, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65:333–341. doi:10.1093/jac/dkp41119959544
   PubMed Web of Science ®Google Scholar
• Guan X, He L, Hu B, et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. Clin Microbiol Infect. 2016;22(Suppl 1):S15–S25. doi:10.1016/j.cmi.2015.11.00426627340
   PubMed Web of Science ®Google Scholar
• Gajdács M, Albericio F. Antibiotic resistance: from the bench to patients. Antibiotics. 2019;8.
   Web of Science ®Google Scholar
• Cassini A, Colzani E, Pini A, et al; On Behalf Of The, BCoDE Consortium. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Euro Surveill. 2018;23(16). doi:10.2807/1560-7917.ES.2018.23.16.17-00454
   PubMedGoogle Scholar